Correct. My earlier comments were of course only about the cardiovascular endpoints. I was not aware of the eGFR data. As Bear said, the difference in eGFR outcomes seems to be so small as to be of little or no concern in my opinion, given the results for CVD and ALP.

I haven't seen the data, but if it's the case that the primary endpoint was about 50% lower in  patients with eGFR < 60, it's obviously very impressive. It will be interesting to see if the FDA accepts that result as definitive, or requires futher trial data in eGFR<60 patients.